Immunovia files US patent application to protect its next-generation test
Rhea-AI Summary
Immunovia (Nasdaq Stockholm: IMMNOV) has filed a US provisional patent application for its next-generation test to detect stage 1 and 2 pancreatic cancer. The application covers methods of diagnosing pancreatic ductal adenocarcinoma (PDAC) using a unique combination of five specific biomarkers. The company plans to submit additional clinical data to strengthen the application and file a PCT application within a year for international protection.
Immunovia aims to launch the new test in the US market in 2025, following a large, independent clinical validation study in Q4 2024. The company estimates that 1.8 million individuals in the USA are at high risk for pancreatic cancer and could benefit from annual surveillance testing.
Positive
- Filing of US provisional patent application to protect intellectual property for next-generation pancreatic cancer detection test
- Plans to file PCT application for international patent protection
- Completion of test development with launch planned for 2025 in the US market
- Large independent clinical validation study scheduled for Q4 2024
- Estimated 1.8 million high-risk individuals in the USA could benefit from annual testing
Negative
- Clinical validation study results not yet available
- Patent approval not guaranteed
- Commercialization timeline extends to 2025, potentially impacting near-term revenue
Insights
As a Biotech Patent Attorney, I find Immunovia's patent application for their next-generation pancreatic cancer detection test highly significant. The filing of a US provisional patent application is a strategic move that provides Immunovia with a 12-month priority period to further develop their invention before filing a full patent application.
The patent claims cover both the unique combination of five biomarkers and the method for combining these biomarkers to generate test results. This dual protection strategy is robust, potentially creating a strong barrier to entry for competitors. The planned PCT application within the next year is a cost-effective approach to secure international patent rights.
However, it's important to note that the success of this patent application will largely depend on the novelty and non-obviousness of Immunovia's biomarker combination and analysis method. The company's plan to submit additional clinical data to the USPTO is wise, as it can strengthen their claims and improve the chances of patent grant.
From an investor's perspective, this patent application, if granted, could provide Immunovia with a significant competitive advantage in the pancreatic cancer diagnostics market for up to 20 years from the filing date. However, investors should be aware that the patent process is lengthy and uncertain and competitors may challenge the patent or develop alternative methods.
As an Oncology Researcher, I'm intrigued by Immunovia's approach to early pancreatic cancer detection. Their focus on stage 1 and 2 pancreatic ductal adenocarcinoma (PDAC) is crucial, as early detection significantly improves survival rates in this aggressive cancer type.
The use of a five-biomarker panel is noteworthy. Most current pancreatic cancer screening methods rely on imaging or single biomarkers like CA19-9, which have limitations in sensitivity and specificity. A multi-biomarker approach could potentially offer improved accuracy, especially for early-stage detection.
However, the true value of this test will be determined by the results of the large, independent clinical validation study planned for Q4 2024. Key factors to watch for will be the test's sensitivity, specificity and positive predictive value, particularly in comparison to existing screening methods.
The estimated 1.8 million high-risk individuals in the USA represent a significant market opportunity. If Immunovia's test proves effective for annual surveillance in this population, it could be a game-changer in pancreatic cancer management.
Investors should note that while promising, the path from patent application to clinically validated and widely adopted test is long and often challenging. The 2025 launch target is ambitious and regulatory hurdles, particularly FDA approval, will be critical milestones to monitor.
The patent application claims methods of diagnosing pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The company is seeking patent protection for the unique combination of five specific biomarkers used in its test, as well as the method for combining these biomarkers to generate a positive or negative test result.
Immunovia filed the provisional patent application with the Patent and Trademark Office (PTO) in
Immunovia also plans to file a single PCT (Patent Cooperation Treaty) application within the next year, enabling the company to seek patent protection for its invention across dozens of countries at one time. Immunovia will later pursue patents in specific high-value commercial markets outside the US.
"Our scientists have invented a breakthrough approach to detecting pancreatic cancer and it's vital we protect that invention," said Jeff Borcherding, CEO of Immunovia.
As previously announced, Immunovia has completed development of its next-generation test to detect stage 1 and 2 pancreatic cancer. Immunovia will conduct a large, independent clinical validation study in fourth quarter 2024 to confirm the accuracy of the Immunovia test. The company is on track to launch the new test in the US in 2025.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-files-us-patent-application-to-protect-its-next-generation-test-302213299.html
SOURCE Immunovia AB
FAQ
What is the purpose of Immunovia's new patent application?
When does Immunovia (IMMNOV) plan to launch its new pancreatic cancer detection test?
How many people could benefit from Immunovia's pancreatic cancer test in the USA?
What type of pancreatic cancer does Immunovia's test aim to detect?
